Home › Blood Disorders › Maryland › Baltimore
Blood Disorders clinical trials in Baltimore, MD
3 studies for Blood Disorders are looking for participants at sites in and around Baltimore (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
RecruitingPhase 3
- The Johns Hopkins University School of Medicine, Baltimore
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
RecruitingPhase 3
- University of Maryland Medical Center, Baltimore
- Johns Hopkins Kimmel Cancer Center, Baltimore
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
RecruitingObservational study
- Johns Hopkins University Hemophilia Treatment Center, Baltimore
About Blood Disorders
Blood disorders affect one or more parts of the blood and prevent your blood from doing its job. Find out about the types, causes, and treatments.
More about Blood Disorders on MedlinePlus
Blood Disorders trials in other cities
- Houston, TX11 studies
- Atlanta, GA11 studies
- Boston, MA10 studies
- Los Angeles, CA10 studies
- New York City, NY9 studies
- The Bronx, NY8 studies
- Durham, NC7 studies
- Nashville, TN7 studies
- Mountain View, CA7 studies
- San Diego, CA6 studies
- Seattle, WA6 studies
- Indianapolis, IN5 studies
Other studies in Baltimore
- Non-Small Cell Lung Cancer60 studies
- Prostate Cancer45 studies
- Breast Cancer44 studies
- Lung Cancer41 studies
- Cancer (all types)36 studies
- Colorectal Cancer30 studies
- Pancreatic Cancer30 studies
- Metastatic Cancer26 studies
- Obesity24 studies
- Bladder Cancer24 studies
- Ovarian Cancer23 studies
- Heart Failure23 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.